Item no. |
HY-15597-50mg |
Manufacturer |
MedChem Express
|
CASRN |
53003-10-4 |
Amount |
50 mg |
Quantity options |
10mM/1mL
10 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Clone |
N/A |
Specific against |
other |
Purity |
98.39 |
Formula |
C42H70O11 |
Citations |
ACS Infect Dis. 2021 Aug 13;7(8):2390-2401.<br/>Acta Biomater. 2022 Aug 23;S1742-7061(22)00501-3.<br/>Anal Chem. 2022 Sep 19.<br/>Biomed J. 2020 Aug;43(4):368-374.<br/>bioRxiv. 2020 Jun.<br/>bioRxiv. 2023 Jan 17.<br/>bioRxiv. 2023 Jun 25.<br/>Biosens Bioelectron. 2024 Jul 1:255:116245.<br/>Cancers. 2020 Aug 5;12(8):2176.<br/>Cell Biosci. 2021 Aug 4;11(1):156.<br/>Cell Commun Signal. 2018 Nov 23;16(1):89.<br/>Cell Death Dis. 2023 Mar 11;14(3):193.<br/>EMBO Mol Med. 2019 Oct;11(10):e9930.<br/>Int J Mol Med. 2019 Oct;44(4):1289-1298.<br/>Int J Mol Sci. 2019 Jun 12;20(12):2861.<br/>Int J Mol Sci. 2023 Mar 21;24(6):5939.<br/>Int J Nanomedicine. 2020 Sep 15;15:6839-6854.<br/>J Bioenerg Biomembr. 2021 Aug 8.<br/>J Control Release. 2020 Oct 10;326:387-395.<br/>Norwegian University of Science and Technology. Department of Clinical and Molecular Medicine. 2021 Oct.<br/>Oncol Rep. 2018 Aug;40(2):877-886.<br/>Pharmacol Res. 2020 May;155:104751.<br/>RSC Adv. 2021 Nov 2;11(56):35331-35341.<br/>Viruses. 2022, 14(8), 1734.<br/>Exp Ther Med. 2020 Mar;19(3):1835-1843.<br/>Int J Pharm. 2023 Feb 24;122779.<br/>[1]Lu D, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13253-7.<br/>[2]Zhou J, et al. Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactiveoxygen species. Toxicol Lett. 2013 Oct 24;222(2):139-45.<br/>[3]Wang F, et al. Salinomycin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells In Vitro and In Vivo. PLoS One. 2012; 7(12): e50638.<br/>[4]Qu H, et al. Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24. Asian Pac J Trop Med. 2015 Jul;8(7):578-82.<br/>[5]Klose J, et al. Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model. PLoS One. 2019 Feb 14;14(2):e0211916.<br/>[6]Naujokat C, et al. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658. |
Smiles |
[H][C@]1([C@](C)(CC2)O[C@]32[C@H](O)C=C[C@]4(O[C@]([H])([C@@H](CC)C([C@@H](C)[C@@H](O)[C@H](C)[C@]5([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]5C)=O)[C@@H](C)C[C@H]4C)O3)CC[C@@](CC)(O)[C@H](C)O1 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
Procoxacin |
Available |
|
Product Description |
Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, selectively inhibits the growth of gram-positive bacteria. Salinomycin is a potent inhibitor of Wnt/β-catenin signaling, blocks Wnt-induced LRP6 phosphorylation. Salinomycin (Procoxacin) shows selective activity against human cancer stem cells[1][2][3]. |
StorageTemperature |
-20°C, 3 years; 4°C, 2 years (Powder) |
Shipping |
Room Temperature |
Manufacturers Applications |
Cancer-Kinase/protease |
MolecularWeight |
751.00 |
Clinical Information |
No Development Reported |
Manufacturers Research Area |
Cancer |
Solubility |
DMSO : ≥ 36.7 mg/mL |
Target |
Antibiotic; Apoptosis; Autophagy; Bacterial; Mitophagy; Parasite; Wnt; β-catenin |
Manufacturers Target |
Antibiotic; Apoptosis; Autophagy; Bacterial; Mitophagy; Parasite; Wnt; β-catenin |
Isoform |
Coccidia |
Manufacturers Pathway |
Anti-infection; Apoptosis; Autophagy; Stem Cell/Wnt |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.